Kodiak Sciences is discontinuing development of tarcocimab tedromer, citing results of the GLEAM and GLIMMER phase 3 studies in diabetic macular edema, according to a press release.
“A successful efficacy, durability and safety outcome in both GLEAM and GLIMMER was the basis of our regulatory and clinical development strategy for tarcocimab,” Kodiak CEO Victor Perlroth, MD, said in the release.
The identically designed randomized controlled studies failed to meet their primary efficacy endpoints of showing noninferior visual acuity gains for tarcocimab dosed every 8 to 24 weeks